Cardiovascular Disease Prevention in Patients With HIV: The REPRIEVE Trial

Cardiovascular Disease Prevention in Patients With HIV: The REPRIEVE Trial
Presenter: Steven K. Grinspoon, MD
Moderator: Judith S. Currier, MD
October 27, 2023
The primary results of the REPRIEVE (Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults) trial were published in the New England Journal of Medicine in July 2023 and show that the statin drug pitavastatin calcium lowers the risk of heart disease in people with HIV by 35%. The results of this important large, randomized trial will have a substantial impact on the health of people with HIV. In this webinar, REPRIEVE principal investigator Dr Steven Grinspoon shared the study findings as well as their implications for individuals with HIV.